Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small cell bronchogenic carcinoma.

M Perloff, J Y Killen, R E Wittes

    Current Problems in Cancer
    |April 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Significant strides in small cell lung cancer (SCBC) treatment improve response rates and survival. Some patients achieve long-term disease-free intervals, suggesting potential cures with current therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2000
    Same author

    Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.

    Cancer journal (Sudbury, Mass.)·2000
    Same author

    Association of angiogenesis in lymph node metastases with outcome of breast cancer.

    Journal of the National Cancer Institute·2000
    Same author

    Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

    Journal of the National Cancer Institute·1999
    Same author

    Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1998
    Same author

    Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1997
    Same journal

    Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

    Current problems in cancer·2026
    Same journal

    Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

    Current problems in cancer·2026
    Same journal

    Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

    Current problems in cancer·2026
    Same journal

    Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

    Current problems in cancer·2026
    Same journal

    Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

    Current problems in cancer·2026
    Same journal

    Advancements and perspectives of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

    Current problems in cancer·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pulmonology

    Background:

    • Small cell lung cancer (SCBC) remains a significant clinical challenge.
    • Advances in treatment have improved outcomes for patients.

    Purpose of the Study:

    • To review the current landscape and future directions in SCBC management.
    • To highlight key advancements in therapeutic strategies.

    Main Methods:

    • Review of existing literature and clinical data on SCBC treatment.
    • Analysis of response rates, survival, and disease-free intervals.

    Main Results:

    • Patients with limited-stage (LD) disease show high response rates (≥80% objective response, ≥50% CR) and improved survival (median OS ≥14 months).
    • A subset of LD patients (15-20%) achieve long-term disease-free survival, indicating potential cure.

    Related Experiment Videos

  • Patients with extensive-stage (ED) disease also demonstrate significant responses (≥80% objective response, ≥20% CR) and survival (median OS ≥7 months).

    • Conclusions:

    • Current SCBC treatments offer substantial benefits, including prolonged survival and disease-free intervals.
    • Ongoing research focuses on optimizing chemotherapy, radiotherapy, surgery, and novel agents for further improvement.